癌症研究
细胞周期蛋白依赖激酶
癌症
癌变
抑制器
CDK抑制剂
E2F1
抑癌基因
细胞生长
车站3
细胞周期
癌细胞
蛋白酶体
细胞周期检查点
生物
细胞生物学
信号转导
遗传学
作者
Amna Parveen,Muhammad Sajid Hamid Akash,Kanwal Rehman,Whang Wan Kyunn
标识
DOI:10.1615/critreveukaryotgeneexpr.v26.i1.60
摘要
Cancer develops due to an imbalance between cell proliferation and cell death. Various mechanisms of carcinogenesis as well as of novel anticancer agents that could be targeted for the treatment of cancer have been proposed by different studies. Among these, p21 is recognized as a potent cyclin-dependent kinase inhibitor that facilitates cell-cycle arrest by interacting with different stimuli such as p53, DNA repair process, CDK, E2F1, MYC, PCNA, STAT3 AP4, proteasomes, K1F, CDX2, and ER-α. p21 acts both as a tumor-suppressor gene and an inhibitor of apoptosis by interacting with various molecules and transition factors. In this review, we discuss the complex role of p21 in the development of cancer and as a target in its treatment. We conclude that, in the future, the tumor-suppressor activity of p21 should be the focus of a novel treatment strategies, which may lead to the devolvement of new and selective anti-cancer agents for the targeted therapy of cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI